China NMPA Drug Inspection - Anhui Taiyuan Traditional Chinese Medicine Pieces Co., Ltd. - Bupleurum

This announcement from the Heilongjiang Provincial Food and Drug Administration, dated September 21, 2018, details findings of substandard drugs and traditional Chinese medicine decoction pieces. Several companies were cited for violations. Beijing Jialin Pharmaceutical Co., Ltd. had two batches of Atorvastatin Calcium Tablets failing identification tests. Harbin Yutai Pharmaceutical Co., Ltd.'s Atractylodes lancea and Cornus officinalis batches showed issues with appearance, identification, impurities, and signs of mold or insect infestation. Anhui Zehua Traditional Chinese Medicine Decoction Pieces Co., Ltd. was cited for substandard appearance in a Bupleurum batch, and Tibet Shenhou Pharmaceutical Co., Ltd.'s Twenty-Five Flavor Coral Pills failed inspection for an unapproved substance, 808 Scarlet. Additionally, multiple batches from Qiqihar Xianhe Traditional Chinese Medicine Decoction Pieces Processing Plant, Bozhou Gongyao Decoction Pieces Factory, and Anhui Youxin Pharmaceutical Co., Ltd. were found substandard in appearance or properties. Significantly, these products were verified as not produced by the labeled manufacturers, suggesting instances of counterfeiting or misrepresentation. In response, regulatory bodies initiated control measures, including sealing and seizing the affected products and ordering a halt to their sale and use. Provincial and local food and drug administration departments are mandated to investigate and prosecute these illegal activities in accordance with Articles 73, 74, and 75 of the Drug Administration Law of the People's Republic of China. Cases suspected of criminal activity will be transferred to public security, and all handling results must be publicly disclosed within three months. This action underscores a commitment to public health and drug quality standards.